WallStreetZenWallStreetZen

NASDAQ: INBS
Intelligent Bio Solutions Inc Stock

$0.67-0.06 (-8.22%)
Updated Feb 3, 2023
INBS Price
$0.67
Fair Value Price
$1.06
Market Cap
$12.37M
52 Week Low
$0.17
52 Week High
$1.60
P/E
-1.25x
P/B
2.38x
P/S
8.36x
PEG
N/A
Dividend Yield
N/A
Revenue
$748.47k
Earnings
-$8.08M
Gross Margin
100%
Operating Margin
-1,078.62%
Profit Margin
-1,079.8%
Debt to Equity
0.96
Operating Cash Flow
-$5M
Beta
1.06
Next Earnings
Feb 9, 2023
Ex-Dividend
N/A
Next Dividend
N/A

INBS Overview

Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Zen Score

Industry Average (30)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how INBS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

INBS ($0.67) is undervalued by 36.39% relative to our estimate of its Fair Value price of $1.06 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
INBS ($0.67) is significantly undervalued by 36.39% relative to our estimate of its Fair Value price of $1.06 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
INBS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more INBS due diligence checks available for Premium users.

Be the first to know about important INBS news, forecast changes, insider trades & much more!

INBS News

Valuation

INBS fair value

Fair Value of INBS stock based on Discounted Cash Flow (DCF)
Price
$0.67
Fair Value
$1.06
Undervalued by
36.77%
INBS ($0.67) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
INBS ($0.67) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
INBS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

INBS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.25x
Industry
59.96x
Market
15.09x

INBS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.38x
Industry
3.75x
INBS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

INBS's financial health

Profit margin

Revenue
$311.3k
Net Income
-$1.2M
Profit Margin
-388.1%
INBS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
INBS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$10.2M
Liabilities
$5.0M
Debt to equity
0.96
INBS's short-term assets ($8.21M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INBS's short-term assets ($8.21M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INBS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$1.9M
Investing
-$474.9k
Financing
$0.0
INBS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

INBS vs Medical Device Stocks

TickerMarket Cap1d %P/EP/B
INBS$12.37M-7.54%-1.25x2.38x
STRR$13.55M-2.72%-0.64x0.34x
AEMD$13.97M-7.73%-0.78x0.70x
AVGR$10.63M+0.70%-0.27x2.15x
NSPR$10.34M+5.08%-0.55x0.47x

Intelligent Bio Solutions Stock FAQ

What is Intelligent Bio Solutions's quote symbol?

NASDAQ: INBS) Intelligent Bio Solutions trades on the NASDAQ under the ticker symbol INBS. Intelligent Bio Solutions stock quotes can also be displayed as NASDAQ: INBS.

If you're new to stock investing, here's how to buy Intelligent Bio Solutions stock.

What is the 52 week high and low for Intelligent Bio Solutions (NASDAQ: INBS)?

(NASDAQ: INBS) Intelligent Bio Solutions's 52-week high was $1.60, and its 52-week low was $0.17. It is currently -57.88% from its 52-week high and 296.47% from its 52-week low.

How much is Intelligent Bio Solutions stock worth today?

(NASDAQ: INBS) Intelligent Bio Solutions currently has 18,352,995 outstanding shares. With Intelligent Bio Solutions stock trading at $0.67 per share, the total value of Intelligent Bio Solutions stock (market capitalization) is $12.37M.

Intelligent Bio Solutions stock was originally listed at a price of $11.02 in Dec 23, 2020. If you had invested in Intelligent Bio Solutions stock at $11.02, your return over the last 2 years would have been -93.88%, for an annualized return of -75.27% (not including any dividends or dividend reinvestments).

How much is Intelligent Bio Solutions's stock price per share?

(NASDAQ: INBS) Intelligent Bio Solutions stock price per share is $0.67 today (as of Feb 3, 2023).

What is Intelligent Bio Solutions's Market Cap?

(NASDAQ: INBS) Intelligent Bio Solutions's market cap is $12.37M, as of Feb 7, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Intelligent Bio Solutions's market cap is calculated by multiplying INBS's current stock price of $0.67 by INBS's total outstanding shares of 18,352,995.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.